North America Human Vaccine Adjuvants Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America Human Vaccine Adjuvants Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America Human Vaccine Adjuvants Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America Human Vaccine Adjuvants Market Regional Analysis

6.2 North America Human Vaccine Adjuvants Market Revenue 2020-2030 (US$ Million)

6.3 North America Human Vaccine Adjuvants Market Forecast Analysis

7. North America Human Vaccine Adjuvants Market Analysis – by Type

7.1 Particulate Adjuvant

7.1.1 Overview
7.1.2 Particulate Adjuvant: North America Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.2 Emulsion Adjuvant

7.2.1 Overview
7.2.2 Emulsion Adjuvant: North America Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.3 Combination Adjuvant

7.3.1 Overview
7.3.2 Combination Adjuvant: North America Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

8. North America Human Vaccine Adjuvants Market Analysis – by Application

8.1 Influenza

8.1.1 Overview
8.1.2 Influenza: North America Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.2 Hepatitis

8.2.1 Overview
8.2.2 Hepatitis: North America Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.3 Human papilloma virus

8.3.1 Overview
8.3.2 Human papilloma virus: North America Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

9. North America Human Vaccine Adjuvants Market Analysis – by End User

9.1 Pharmaceutical and Biotechnology Companies

9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: North America Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

9.2 CMOs and CROs

9.2.1 Overview
9.2.2 CMOs and CROs: North America Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

10. North America Human Vaccine Adjuvants Market – North America Analysis

10.1 Overview

10.2 North America

10.2.1 North America Human Vaccine Adjuvants Market Breakdown, by Key Country, 2023 and 2030 (%)
10.2.1.1 North America Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.2.1.1 US: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.1.1 US: North America Human Vaccine Adjuvants Market Breakdown, by Type
10.2.1.1.2 US: North America Human Vaccine Adjuvants Market Breakdown, by Application
10.2.1.1.3 US: North America Human Vaccine Adjuvants Market Breakdown, by End User

10.2.1.2 Canada: North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.2.1 Canada: North America Human Vaccine Adjuvants Market Breakdown, by Type
10.2.1.2.2 Canada: North America Human Vaccine Adjuvants Market Breakdown, by Application
10.2.1.2.3 Canada: North America Human Vaccine Adjuvants Market Breakdown, by End User

10.2.1.3 Mexico : North America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.3.1 Mexico : North America Human Vaccine Adjuvants Market Breakdown, by Type
10.2.1.3.2 Mexico : North America Human Vaccine Adjuvants Market Breakdown, by Application
10.2.1.3.3 Mexico : North America Human Vaccine Adjuvants Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Creative Biolabs Inc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Croda International Plc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 CSL Ltd

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Dynavax Technologies Corp

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Hawaii Biotech Inc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Novartis AG

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Novavax Inc

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Phibro Animal Health Corp

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Seppic SA

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 SPI Pharma Inc

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

North America Human Vaccine Adjuvants Market

Analysis - by Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), and End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others)